However, there are number of issues and barriers unique to developing treatments for orphan diseases
that pharmaceutical companies face and which are often not well understood by the general public.
James joins Oxyrane from his previous role as US Head of Regulatory Affairs for rare and orphan diseases
at Shire Human Genetic Therapies.
The Orphan Disease
Treatment Institute was financed through joint investment from Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital Co.
Data and analysis on the global orphan disease
therapeutics in genetic disorders in the leading geographies of the world- the US, the UK, Germany, France, Italy, Spain, and Japan.
BioXcel's PharmGPS(TM) Orphan Disease
suite addresses this complexity in a highly systematic manner to explore innovative ideas and deliver business value.
GBI Research's analysis of industry trends suggests that the orphan disease
therapeutics market is likely to see a steady increase in value over the forecast period.
Numerous tables and figures are weaved within the report to support the findings and illustrate the trends and activities in orphan disease
partnering and dealmaking since 2010.
The report also includes insights into the orphan diseases
therapeutics in Oncology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the Oncology orphan disease
Not only does such focus help those affected by rare diseases, of which there are 25 million people in the United States alone, it also furthers the aim of precision medicine and substantiates the envisioned high returns on the R&D investment, particularly for drugs with multiple orphan disease
GBI Research, the leading business intelligence provider, has released its latest research Orphan Diseases
Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment, which provides insights into the CNS orphan disease
therapeutics market until 2017.
Formation of the new Penn Center for Orphan Disease
Research and Therapy was catalyzed by a $10 million gift from an anonymous donor, whose vision matched that of Penn Medicine in developing treatments for these diseases.
WASHINGTON -- Thought leaders from dozens of biotech and pharmaceutical corporations from across the globe will gather June 19 - 20 to discuss innovations and regulations pertaining to Orphan Diseases
, at the 2012 Orphan Disease
Forum, as part of the 2012 BIO International Convention in Boston, MA.